In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth a...
AbZelect™ and AbZelectPRO™ platforms enable the rapid generation and selection of high-yielding mammalian CHO cell lines for therapeutic protei...
he added capacity will further enhance WuXi Biologics’ commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people...
The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1000 m...
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approxi...
Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (...
In addition, Lonza, Medivir's partner for process development and manufacture of drug substance, has developed a process suitable for commercial manufactur...
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium ...
The complexity of new biologics means that these life-changing therapeutics require complicated development and manufacturing processes. Product-specific c...
As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete ...
The company invited supplier companies and external ESG specialists to discuss ESG-related requirements and recommendations as well as share successful cas...
This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination w...
Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecule...
© 2025 Biopharma Boardroom. All Rights Reserved.
